Navidea Biopharmaceuticals (NYSEAMERICAN:NAVB) Receives Buy Rating from HC Wainwright

Share on StockTwits

HC Wainwright reiterated their buy rating on shares of Navidea Biopharmaceuticals (NYSEAMERICAN:NAVB) in a research note released on Monday, The Fly reports. HC Wainwright currently has a $8.00 price objective on the biopharmaceutical company’s stock, up from their previous price objective of $6.00.

Other equities research analysts have also issued reports about the company. Maxim Group restated a buy rating and set a $7.00 price objective on shares of Navidea Biopharmaceuticals in a research report on Friday, August 14th. Zacks Investment Research upgraded Navidea Biopharmaceuticals from a sell rating to a hold rating in a research report on Thursday, July 23rd.

NYSEAMERICAN:NAVB opened at $3.27 on Monday. Navidea Biopharmaceuticals has a 1-year low of $0.50 and a 1-year high of $5.36.

Navidea Biopharmaceuticals (NYSEAMERICAN:NAVB) last released its quarterly earnings results on Thursday, August 13th. The biopharmaceutical company reported ($0.11) earnings per share for the quarter, beating the Zacks’ consensus estimate of ($0.12) by $0.01.

Several institutional investors have recently made changes to their positions in the company. HighTower Advisors LLC lifted its holdings in shares of Navidea Biopharmaceuticals by 82.5% during the 2nd quarter. HighTower Advisors LLC now owns 27,540 shares of the biopharmaceutical company’s stock valued at $109,000 after buying an additional 12,450 shares during the last quarter. Virtu Financial LLC acquired a new stake in shares of Navidea Biopharmaceuticals during the 2nd quarter valued at about $69,000. Finally, OTA Financial Group L.P. acquired a new stake in shares of Navidea Biopharmaceuticals during the 2nd quarter valued at about $258,000.

About Navidea Biopharmaceuticals

Navidea Biopharmaceuticals, Inc, a biopharmaceutical company, focuses on the development and commercialization of precision immunodiagnostic agents and immunotherapeutics. The company operates in two segments, Diagnostic Substances and Therapeutic Development Programs. The company develops Manocept platform to target the CD206 mannose receptor expressed on activated macrophages; and NAV4694, a fluorine-18 labeled positron emission tomography imaging agent for use as an aid in the imaging and evaluation of patients with signs or symptoms of Alzheimers disease and mild cognitive impairment.

Further Reading: What are the qualifications of a portfolio manager?

The Fly

Receive News & Ratings for Navidea Biopharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Navidea Biopharmaceuticals and related companies with's FREE daily email newsletter.

Leave a Reply